Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of QLC7401 in Hypercholesterolemia and Mixed Hyperlipidemia
NCT06750341Phase 2Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Feb 2025
- Primary completion
- Jun 2026
- Modality
- Conjugated siRNA, Peptide-Drug Conjugates, Small Molecules
01
Overview
A Phase 2 trial of rbd7022 in hypercholesterolemia, mixed hyperlipidemia, sponsored by Qilu Pharmaceutical. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
rbd7022
03
Conditions
hypercholesterolemiamixed hyperlipidemia
Beyond the preview
Go deeper on NCT06750341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06750341.